'Ocular hypertension' presentation slideshows

New Care Pathways in Glaucoma

Stephen A. Vernon DM FRCS FRCOphth DO. New Care Pathways in Glaucoma. DEPARTMENT OF OPHTHALMOLOGY UNIVERSITY HOSPITAL NOTTINGHAM UK. UK population by age - 2001. Age range. BMES PREVALENCE OF POAG. <60 60-69 70-79 >80. Age Group. Estimated numbers of glaucomas in UK by age.

693 views • 56 slides

????? 11 ?"? ???? ??? ?"? ???? ???? ???? ?"? ???? ??? ??????? ?"? ???? ????????

????? 11 ?"? ???? ??? ?"? ???? ???? ???? ?"? ???? ??? ??????? ?"? ???? ???????? ?"? ????? ??????? ?????: ?"? ??????? ??????? ?"? ????? ???. Case Presentation. A 30 yo female Underwent PRK for high myopia of -8.0D OD and -7.5D OS,

386 views • 15 slides

MOUSUMI SAIKIA M.Optom , B.Optom

Clinical Effectiveness Of Contrast Sensitivity Function In Patients With Primary Open Angle Glaucoma (POAG) And Ocular Hypertension (OHT ). Under Guidance of DR. VIDYA CHELERKAR MS, DNB. MOUSUMI SAIKIA M.Optom , B.Optom

346 views • 8 slides

Ocular Hypertension: Causes, Symptoms, Daignosis, Prevention and Treatment

Ocular Hypertension is a pressure in your eyes that is higher than normal.

465 views • 8 slides

Ocular Hypertension Global Clinical Trials, 2016-Latest Report

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type

138 views • 7 slides

Ocular Hypertension Therapeutic Pipeline Review, H1 2015

246 views • 6 slides

Ocular Hypertension Pipeline Review H2 2015

This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases

205 views • 6 slides

Ocular Hypertension Market Share, Trends and Forecasts 2016

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

88 views • 3 slides